Status:
COMPLETED
Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC
Lead Sponsor:
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
19-87 years
Brief Summary
This study is an observational study aimed at investigating the potential of new inflammatory markers to predict treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing a...
Detailed Description
This observational study investigates the potential of new inflammatory markers to predict treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing anti-PD-1 antibody nivo...
Eligibility Criteria
Inclusion
- Age: Participants must be ≥18 and ≤87 years old. Diagnosis: Patients must have been diagnosed with metastatic renal cell carcinoma (mRCC).
- Treatment: Only patients receiving nivolumab treatment for metastatic renal cell carcinoma are included.
- Consent: Written informed consent was obtained from all participants
Exclusion
- Other Active Cancers: Patients with concurrent active malignancies were excluded from the study.
- Prior Immunotherapy Treatment: Patients who had previously received any form of immunotherapy (anti-PD-1, anti-PD-L1, or similar immunological agents) were excluded.
- Uncontrolled Systemic Diseases: Patients with severe, uncontrolled systemic diseases (e.g., significant cardiovascular, pulmonary, or liver diseases) were not included in the study.
- Active Infections: Patients with serious active infections, such as active tuberculosis, HIV infection, or chronic hepatitis B or C, were excluded.
- Pregnancy and Breastfeeding: Pregnant or breastfeeding women were not eligible for inclusion in the study.
- Immunodeficiency or Immunosuppressive Therapy: Patients with immunodeficiency or those receiving immunosuppressive therapy (e.g., corticosteroids) were excluded from the study.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT06607809
Start Date
February 1 2022
End Date
January 1 2024
Last Update
October 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Health Science University Kartal Dr. Lütfi Kirdar City Hospital
Istanbul, Kartal, Turkey (Türkiye), 34865